Assenagon Asset Management S.A. Buys 49,050 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. raised its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,856 shares of the biotechnology company's stock after buying an additional 49,050 shares during the quarter. Assenagon Asset Management S.A. owned 0.91% of Enanta Pharmaceuticals worth $1,109,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in shares of Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 1,548 shares during the period. American Century Companies Inc. increased its stake in Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock worth $362,000 after acquiring an additional 7,287 shares during the period. Cubist Systematic Strategies LLC raised its holdings in Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company's stock valued at $588,000 after acquiring an additional 18,003 shares in the last quarter. US Bancorp DE lifted its position in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares during the period. Finally, Quest Partners LLC grew its holdings in shares of Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company's stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Institutional investors own 94.99% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. HC Wainwright dropped their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, December 24th. Finally, Robert W. Baird reduced their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $17.25.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares of the company's stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 13.64% of the company's stock.

Enanta Pharmaceuticals Trading Down 0.2 %

Enanta Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $5.53. The company's stock had a trading volume of 317,144 shares, compared to its average volume of 684,612. The stock has a market cap of $117.18 million, a PE ratio of -1.01 and a beta of 0.56. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.71 and a 52 week high of $17.80. The business has a 50-day moving average price of $6.73 and a 200-day moving average price of $10.43.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company's revenue for the quarter was down 22.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.33) earnings per share. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.93 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.